Login to Your Account


Exelixis and Ipsen gearing up for ESMO as first-line RCC bids clash

By Randy Osborne
Staff Writer

Wednesday, October 5, 2016

As buzz grows approaching the ESMO meeting in Copenhagen this weekend, therapeutic prospects in first-line renal cell carcinoma (RCC) have drawn particular interest, with big pharma and biotech players waiting for data rollouts.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription